Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21682481 | 1.00 | GABRR1 (0.48) | GABRR1GRM2CYP2C19GRM4MEN1 | |
| SCHEMBL26615125 | 1.00 | GABRR1 (0.48) | GABRR1GRM2CYP2C19GRM4MEN1 | |
| Hydrochloric Acid SCHEMBL12505253 | 0.98 | GABRR1 (0.46) | GABRR1GRM2CYP2C19GRM4MEN1 | |
| Hydrochloric Acid SCHEMBL12505254 | 0.98 | GABRR1 (0.46) | GABRR1GRM2CYP2C19GRM4MEN1 | |
| Hydrochloric Acid SCHEMBL12505252 | 0.98 | GABRR1 (0.46) | GABRR1GRM2CYP2C19GRM4MEN1 | |
| SCHEMBL3620776 | 0.83 | GABRR1 (0.39) | GABRR1GRM2GRM6 | |
| SCHEMBL19816446 | 0.83 | GABRR1 (0.39) | GABRR1GRM2GRM6 | |
| SCHEMBL4627762 | 0.83 | GABRR1 (0.39) | GABRR1GRM2GRM6 | |
| SCHEMBL3832575 | 0.83 | GABRR1 (0.39) | GABRR1GRM2GRM6 | |
| SCHEMBL3620778 | 0.83 | GABRR1 (0.39) | GABRR1GRM2GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | GABRR1 2395/4885GRM2 1215/4885CYP2C19 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.